Lenalidomide Orion (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex. This binding changes the complex’s substrate specificity, leading to the degradation of transcription factors Ikaros and Aiolos. The result is reduced tumor angiogenesis, enhanced immune‑mediated tumor cell killing, and direct inhibition of malignant cell proliferation.

The prescribed dose of Lenalidomide Orion is individualized by the treating physician based on the specific indication, disease stage, renal function, and patient tolerance. Dosage adjustments may be required over the course of therapy, and patients should follow the exact regimen provided by their healthcare professional.

Lenalidomide Orion is classified as Pregnancy Category X because it is known to cause fetal harm. It is contraindicated in pregnancy, and effective contraception must be used by both male and female patients of reproductive potential. The drug is also not recommended while breastfeeding, as it may be excreted in milk and affect the infant.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lenalidomide belongs to the immunomodulatory imide drug (IMiD) class, sharing a mechanism with thalidomide but offering greater potency and a more favorable safety profile. Compared with thalidomide, lenalidomide typically shows higher response rates in multiple myeloma and lower incidence of peripheral neuropathy, though both require careful monitoring for thromboembolic events.

Lenalidomide Orion should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product in a dry place and avoid exposure to extreme temperatures or humidity, which could compromise tablet integrity.

Lenalidomide Orion is taken orally, usually once daily, with or without food as directed by the prescribing clinician. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious risks include venous thromboembolism, severe infections due to neutropenia, secondary primary malignancies, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should promptly report signs of clotting, fever, unexplained bruising, or severe rash to their physician.

Lenalidomide Orion should not be used by individuals who are pregnant, planning to become pregnant, or not using reliable contraception. It is also contraindicated in patients with known hypersensitivity to lenalidomide or any component of the formulation, and caution is advised in those with severe renal impairment or uncontrolled infections.